Brawn Biotech (530207)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹24.80, Brawn Biotech has a market cap of just ₹8 crore. In Graham's language, small size is not a margin of safety. The latest quarter reports sales of ₹4 crore and net profit of ₹0 crore; the trailing P/E shows 0.00, which tells me current earnings do not exist. Sales growth of 12.24% is nice but meaningless if the bottom line is zero. ROE is -3.24% and ROCE is -42.52%; that is capital destruction. The 111.63% profit growth is a statistical illusion from a very low or negative base. Book value is ₹15.45, so at ₹24.80 I am paying 1.61 times book for a business that earns negative returns on equity. There is no dividend, and with promoter holding and debt/equity both listed as N/A, I cannot properly assess governance or leverage. The Piotroski F-score of 6/9 offers some sign of operational improvement, but it is not a substitute for actual earnings. Is there a moat? I see no evidence of pricing power or durable advantage in the pharma space from these numbers. This is a watchlist candidate at best, not an investment. I want a business with predictable earnings, high returns on capital, and management I can trust. Brawn Biotech fails all tests at this price. If it continues to grow sales and converts those sales into consistent positive net profit, with ROE turning positive, I might revisit. But as of now, the risk/reward is unattractive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer